Literature DB >> 27796473

[Systemic sclerosis : What is currently available for treatment?]

M O Becker1.   

Abstract

Systemic sclerosis (scleroderma) is a rheumatologic disease characterised not only by inflammation/autoimmunity, but also by tissue fibrosis and vascular lesions. The therapeutic approach to patients is dictated by the organ involvement and includes treatment of vascular and fibrotic disease features beyond mere immunosuppression. Fibrotic features in particular, are still inadequately treated, whereas many drugs have been tested for vascular complications within recent years. In this review, the currently available treatment options for this rare disease are presented. Therapy options in systemic sclerosis have changed over the past 10 years and this trend will also continue in the future.

Entities:  

Keywords:  Fibrosis, lung; Fibrosis, skin; Hematopoietic stem cell transplantation; Immunosuppression; Pulmonary arterial hypertension

Mesh:

Substances:

Year:  2016        PMID: 27796473     DOI: 10.1007/s00108-016-0148-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  99 in total

1.  Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

Authors:  F H van den Hoogen; A M Boerbooms; A J Swaak; J J Rasker; H J van Lier; L B van de Putte
Journal:  Br J Rheumatol       Date:  1996-04

2.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

Authors:  Paul J DeMarco; Michael H Weisman; James R Seibold; Daniel E Furst; Weng Kee Wong; Eric L Hurwitz; Maureen Mayes; Barbara White; Fredrick Wigley; Walter Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Journal:  Arthritis Rheum       Date:  2002-11

3.  Long-term outcomes of scleroderma renal crisis.

Authors:  V D Steen; T A Medsger
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

4.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

5.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

6.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Authors:  N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

7.  Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.

Authors:  V Smith; J T Van Praet; B Vandooren; B Van der Cruyssen; J-M Naeyaert; S Decuman; D Elewaut; F De Keyser
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

8.  Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.

Authors:  Alice Bérezné; Brigitte Ranque; Dominique Valeyre; Michel Brauner; Yannick Allanore; David Launay; Véronique Le Guern; Jean-Emmanuel Kahn; Louis-Jean Couderc; Joël Constans; Pascal Cohen; Alfred Mahr; Christian Pagnoux; Eric Hachulla; André Kahan; Jean Cabane; Loïc Guillevin; Luc Mouthon
Journal:  J Rheumatol       Date:  2008-05-01       Impact factor: 4.666

Review 9.  Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

10.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.